<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101733</url>
  </required_header>
  <id_info>
    <org_study_id>1318/2021</org_study_id>
    <nct_id>NCT05101733</nct_id>
  </id_info>
  <brief_title>Mold Allergy in Austria: Clinical Relevance of Alternaria Alternata and Related Species</brief_title>
  <official_title>Pilot Study Regarding Mold Allergy in Austria: Clinical Relevance of Alternaria Alternata and Related Species</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mold allergies are becoming increasingly important among the population. Increasing amounts&#xD;
      of fungal spores are analyzed in air-samples because of urbanization, industrialization of&#xD;
      food products and climate change. Mold also grows indoor and hence lead to additional health&#xD;
      complaints.&#xD;
&#xD;
      Alternaria alternata, and its only major allergen Alt a 1, is the most important fungus for&#xD;
      allergy sufferers. Alternaria alternata can not only cause allergic symptoms but can also&#xD;
      cause intensified asthmatic symptoms.&#xD;
&#xD;
      Besides Alternaria alternata, there are over 700 other species of the genus Alternaria. The&#xD;
      influence of these other species on allergic symptoms is poorly understood.&#xD;
&#xD;
      Furthermore, prevalence and incidence of an allergy to Alternaria alternata among the&#xD;
      Austrian population is not known. Estimates range between 1-5% among the Austrian population.&#xD;
&#xD;
      This study aims to further investigate the incidence and characteristics of an allergy to&#xD;
      Alternaria in Austria. This will be investigated with the help of participants (50 Alternaria&#xD;
      allergy sufferers and 20 non allergic participants), spore counts in Austria and&#xD;
      crowd-sourced symptom data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence, Immunoglobulin-E (IgE)-antibodies to selected Alternaria species</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the prevalence of sensitization to multiple Alternaria species in the Austrian population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine-profile (e.g. Interleukin-13, Interleukin-5, Interleukin-10, TNFalpha, IFNgamma) upon Alt a 1 incubation</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in the immun response when ligand-binding mononuclear cells from the blood to Alt a 1, characterized by the cytokine profile (Th1/Th2/regulatory) and the cell population (B- and T-cells, macrophages/monocytes)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Fungal Allergy</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Alternaria allergy sufferers</arm_group_label>
    <description>50 people suffering from an allergy to Alternaria. These participants receive a questionnaire, a Skin-Prick-Test, a blood draw and nasal provocation with collection of nasal secretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-allergic participants</arm_group_label>
    <description>Non allergic participants (20) receive a questionnaire, a blood draw and collection of nasal secretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal provocation</intervention_name>
    <description>Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device</description>
    <arm_group_label>Alternaria allergy sufferers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin-Prick Test</intervention_name>
    <description>Skin-Prick-Test is administered to determine an allergy against Alternaria</description>
    <arm_group_label>Alternaria allergy sufferers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>For further analysis</description>
    <arm_group_label>Alternaria allergy sufferers</arm_group_label>
    <arm_group_label>Non-allergic participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Collection of nasal secretion</intervention_name>
    <description>Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray</description>
    <arm_group_label>Alternaria allergy sufferers</arm_group_label>
    <arm_group_label>Non-allergic participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are recruited with the help of advertisements on the social media pages of the&#xD;
        Austrian Pollen Information Service and on the pollen diary app&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants will be healthy people over 18 years of age. Allergic participants should&#xD;
             have an allergic reaction against Alternaria, visible in the Skin-Prick-Test.&#xD;
             Furthermore symptom data in the pollen diary of the Austrian Pollen Information&#xD;
             Service should be existing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects participating in a pharmacological study, pregnant subjects and subjects with&#xD;
             an existing infectious- and/or autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika Jensen-Jarolim, Univ.-Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pathophysiology and Allergy Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Berger, Dr.</last_name>
    <phone>+4369918939871</phone>
    <email>markus.berger@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Markus Berger</investigator_full_name>
    <investigator_title>Dr. med. univ.</investigator_title>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Fungal allergy</keyword>
  <keyword>Alternaria alternata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

